Activate GIPR in the brainstem and appetite falls. Block it in the hypothalamus and fullness signals work better. Two opposite drugs, two circuits, same outcome — and two companies betting on each.
Isotope labelling traced what gut bacteria actually eat when fibre runs short. The answer is the mucus layer protecting your intestinal wall — and the byproducts are toxic.
Hundreds of people in a trial can see unblinded data. A market paying out on the result gives every one of them a reason to trade on it.
Egg-grown flu vaccines force a strain guess months ahead. mRNA compresses that lead time — which is the actual argument, not the 27%.
Comirnaty went from $38 billion to $4.4 billion in three years. Everything in this quarter’s results is a response to that single line.
Everyone studies APOE4, the risk gene. Its protective counterpart may work by keeping neuronal DNA intact — a mechanism nobody was targeting.
Approved in Japan since 2020. Crystalys bought the Western rights and $130 million to run the trials regulators here still require.
The acquisition brings 100,000 pediatric text messages. The data is the asset, and children are where AI accuracy claims face the hardest scrutiny.
Nearly 70% of US counties have no gastroenterologist. That access gap, more than the clinical fit, is what a virtual-care acquisition is buying.
A bean protein that traps virus particles, delivered by chewing. Ex vivo only — no person has yet chewed it in a trial.
Omega fats entered natural killer cells through a receptor called LRP5 and dialled down the metabolism those cells need to attack tumours. Deleting the receptor made them better killers.
Polyamines turn out to be iron storage lockers. Cancer cells need high polyamine levels to grow — which may be exactly what makes them vulnerable to having those lockers opened.